Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1016/j.ijid.2020.05.118

http://scihub22266oqcxt.onion/10.1016/j.ijid.2020.05.118
suck pdf from google scholar
32497796!7263262!32497796
unlimited free pdf from europmc32497796    free
PDF from PMC    free
html from PMC    free
PDF vom PMID32497796  :  Publisher
PDF vom PMID32497796 :   free
PDF vom PMID32497796

suck abstract from ncbi

pmid32497796
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Combination of thrombolytic and immunosuppressive therapy for coronavirus disease 2019: A case report #MMPMID32497796
  • Papamichalis P; Papadogoulas A; Katsiafylloudis P; Skoura AL; Papamichalis M; Neou E; Papadopoulos D; Karagiannis S; Zafeiridis T; Babalis D; Komnos A
  • Int J Infect Dis 2020[Aug]; 97 (ä): 90-93 PMID32497796show ga
  • In a proportion of patients, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes a multisystem syndrome characterized by hyperinflammation, acute respiratory distress syndrome (ARDS), and hypercoagulability. A 68-year-old man with coronavirus disease 2019 (COVID-19) was admitted to the intensive care unit with respiratory failure, cytokine release syndrome (CRS), and skin ischemia - microthrombosis. Specific coagulation and inflammatory markers (D-dimer, ferritin, and C-reactive protein), along with the clinical picture, triggered the trial of recombinant tissue plasminogen activator (rt-PA) and tocilizumab. This was followed by resolution of the skin ischemia and CRS, while respiratory parameters improved. No major complications associated with rt-PA or tocilizumab occurred. The combination of rt-PA with targeted anti-inflammatory treatment could be a new therapeutic option for patients with COVID-19, ARDS, hyperinflammation, and increased blood viscosity.
  • |*Betacoronavirus[MESH]
  • |Aged[MESH]
  • |Antibodies, Monoclonal, Humanized/*therapeutic use[MESH]
  • |COVID-19[MESH]
  • |Coronavirus Infections/*drug therapy[MESH]
  • |Drug Combinations[MESH]
  • |Fibrinolytic Agents/*therapeutic use[MESH]
  • |Humans[MESH]
  • |Immunosuppressive Agents/*therapeutic use[MESH]
  • |Male[MESH]
  • |Pandemics[MESH]
  • |Pneumonia, Viral/*drug therapy[MESH]
  • |SARS-CoV-2[MESH]
  • |Tissue Plasminogen Activator/*therapeutic use[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    90 ä.97 2020